Literature DB >> 16109774

Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds.

Fabrizio Martelli1, Barbara Ghinassi, Barbara Panetta, Elena Alfani, Valentina Gatta, Alessandro Pancrazzi, Costanza Bogani, Alessandro Maria Vannucchi, Francesco Paoletti, Giovanni Migliaccio, Anna Rita Migliaccio.   

Abstract

All mice harboring the X-linked Gata1low mutation in a predominantly CD1 background are born anemic and thrombocytopenic. They recover from anemia at 1 month of age but remain thrombocytopenic all their life and develop myelofibrosis, a syndrome similar to human idiopathic myelofibrosis, at 12 months. The effects of the genetic background on the myelofibrosis developed by Gata1low mice was assessed by introducing the mutation, by standard genetic approaches, in the C57BL/6 and DBA/2 backgrounds and by analyzing the phenotype of the different mutants at 12 to 13 (by histology) and 16 to 20 (by cytofluorimetry) months of age. Although all the Gata1low mice developed fibrosis at 12 to 13 months, variegations were observed in the severity of the phenotype expressed by mutants of different backgrounds. In C57BL/6 mice, the mutation was no longer inherited in a Mendelian fashion, and fibrosis was associated with massive osteosclerosis. Instead, DBA/2 mutants, although severely anemic, expressed limited fibrosis and osteosclerosis and did not present tear-drop poikilocytes in blood or extramedullary hemopoiesis in liver up to 20 months of age. We propose that the variegation in myelofibrosis expressed by Gata1low mutants of different strains might represent a model to study the variability of the clinical picture of the human disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109774     DOI: 10.1182/blood-2005-03-1060

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.

Authors:  Maria Verrucci; Alessandro Pancrazzi; Miguel Aracil; Fabrizio Martelli; Paola Guglielmelli; Maria Zingariello; Barbara Ghinassi; Emanuela D'Amore; José Jimeno; Alessandro M Vannucchi; Anna Rita Migliaccio
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor.

Authors:  Barbara Ghinassi; Massimo Sanchez; Fabrizio Martelli; Giovanni Amabile; Alessandro Maria Vannucchi; Giovanni Migliaccio; Stuart H Orkin; Anna Rita Migliaccio
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

Review 3.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 4.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

5.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

6.  Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Massimo Sanchez; Mauro Valeri; Giovanni Migliaccio; Alessandro Maria Vannucchi; Maria Zingariello; Angela Di Baldassarre; Barbara Ghinassi; Rosa Alba Rana; Yvette van Hensbergen; Willem E Fibbe
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

7.  Evidence for organ-specific stem cell microenvironments.

Authors:  Barbara Ghinassi; Fabrizio Martelli; Maria Verrucci; Emanuela D'Amore; Giovanni Migliaccio; Alessandro Maria Vannucchi; Ronald Hoffman; Anna Rita Migliaccio
Journal:  J Cell Physiol       Date:  2010-05       Impact factor: 6.384

8.  Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Alessandro Maria Vannucchi; Hongyu Ni; Mingjiang Xu; Yi Jiang; Betty Nakamoto; Thalia Papayannopoulou; Ronald Hoffman
Journal:  Exp Hematol       Date:  2008-02       Impact factor: 3.084

9.  A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis.

Authors:  Maria Zingariello; Alessandra Ruggeri; Fabrizio Martelli; Manuela Marra; Laura Sancillo; Ilaria Ceglia; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Am J Blood Res       Date:  2015-12-25

10.  Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.

Authors:  Maria Zingariello; Fabrizio Martelli; Fiorella Ciaffoni; Francesca Masiello; Barbara Ghinassi; Emanuela D'Amore; Margherita Massa; Giovanni Barosi; Laura Sancillo; Xiaochun Li; Judith D Goldberg; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Blood       Date:  2013-03-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.